[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
September 1963

Studies of Prematures Given Erythromycin Estolate

Author Affiliations

Joan Hodgman, MD, University of Southern California School of Medicine, 2025 Zonal Ave, Los Angeles 33, Calif.; Assistant Clinical Professor of Pediatrics (Dr. Burns) and Associate Professor of Pediatrics (Dr. Hodgman), University of Southern California, School of Medicine.; From the Department of Pediatrics, University of Southern California, School of Medicine, and the Premature Center of the Los Angeles County General Hospital.

Am J Dis Child. 1963;106(3):280-288. doi:10.1001/archpedi.1963.02080050282005

Erythromycin has been recommended for the treatment of staphylococcal and streptococcal infections in newborn infants even though few studies of its use in this age group have been reported. Fujii et al1 published serum levels for various doses of erythromycin in the full-term infant. No similar study has been reported for the premature infant. Reichelderfer et al2 noted no toxic reaction or accumulation of erythromycin in a study of 11 newborn infants of whom four were premature. He obtained serum levels on two of the prematures. Isenberg et al3 reported the recovery without toxic reactions of eight infected premature infants treated with erythromycin.

Michael et al4,5 reported animal studies showing that chloramphenicol, penicillin, novobiocin, and tetracycline were more toxic for the newborn rat than the adult rat, while streptomycin was not. That the newborn infant may respond to drugs differently than the adult is amply demonstrated

First Page Preview View Large
First page PDF preview
First page PDF preview